GlassScriptPhysician profile
Michelle Y West
NPI 1194483099
$11,184.71
in general payments reported to CMS, 2019-2025
54 companies · $745 in 2025
The $745 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,281 · 2023: $4,213 · 2024: $2,946 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,648 · Education: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,647.86 |
| Education | $255.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $903.78 | 2022-2025 | Enhertu, Tagrisso, Calquence |
| Janssen Biotech, INC. | $840.00 | 2022-2024 | Darzalex, Tecvayli, Carvykti |
| Merck Sharp & Dohme LLC | $705.08 | 2022-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $688.51 | 2022-2025 | Opdivo, Opdualag, Pomalyst |
| Novartis Pharmaceuticals Corporation | $664.71 | 2022-2025 | |
| Incyte Corporation | $572.01 | 2022-2025 | Jakafi, Pemazyre, Monjuvi |
| Astellas Pharma US INC | $461.51 | 2022-2025 | Padcev, Xtandi, Vyloy |
| Seagen INC. | $450.60 | 2022-2023 | Padcev, Adcetris |
| Pfizer INC. | $389.00 | 2022-2024 | |
| Abbvie INC. | $334.55 | 2022-2025 | |
| Genzyme Corporation | $326.81 | 2022-2024 | |
| Genentech USA, INC. | $301.22 | 2022-2025 | Phesgo, Perjeta, Venclexta |
| Daiichi Sankyo INC. | $283.43 | 2022-2024 | Enhertu, Injectafer |
| Eisai INC. | $280.56 | 2022-2024 | |
| Lilly USA, LLC | $266.35 | 2022-2025 | Jaypirca, Retevmo, Verzenio |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $253.55 | 2023-2025 | Xpovio |
| Celgene Corporation | $235.60 | 2022-2025 | Reblozyl, Pomalyst |
| Bayer Healthcare Pharmaceuticals INC. | $214.02 | 2022-2025 | |
| Exelixis INC. | $188.60 | 2022-2025 | Cabometyx |
| Morphosys, US INC. | $186.20 | 2022-2024 | Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $173.50 | 2022-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Aveo Pharmaceuticals, INC. | $168.54 | 2022-2024 | Fotivda |
| Gilead Sciences, INC. | $167.27 | 2022-2025 | Trodelvy |
| Puma Biotechnology, INC. | $158.45 | 2022-2025 | Nerlynx |
| Amgen INC. | $150.92 | 2022-2023 | Vectibix, Nplate, Xgeva |
| Regeneron Healthcare Solutions, INC. | $148.04 | 2022-2024 | Libtayo |
| Myriad Genetic Laboratories, INC. | $142.04 | 2022-2023 | Myrisk |
| Mirati Therapeutics, INC. | $123.11 | 2023-2024 | Krazati |
| Tersera Therapeutics LLC | $118.86 | 2022-2024 | Zoladex |
| Beigene USA, INC. | $112.65 | 2022-2024 | Brukinsa, Tevimbra |
| Ipsen Biopharmaceuticals, INC | $112.33 | 2022-2025 | Onivyde, Tazverik |
| Emd Serono, INC. | $108.39 | 2023-2025 | Bavencio |
| Glaxosmithkline, LLC. | $106.22 | 2023-2024 | Ojjaara |
| Sanofi-Aventis U.S. LLC | $99.95 | 2022 | |
| Sobi, INC | $99.61 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $92.54 | 2022-2024 | Ultomiris |
| Genmab U.S., INC. | $84.60 | 2023-2024 | Epkinly |
| Array Biopharma INC | $55.70 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Jazz Pharmaceuticals INC. | $51.88 | 2022-2024 | |
| Stemline Therapeutics INC. | $48.13 | 2023 | Orserdu, Elzonris |
| Rigel Pharmaceuticals, INC. | $43.45 | 2022-2023 | Rezlidhia, Tavalisse |
| Taiho Oncology, INC. | $39.47 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $33.53 | 2024-2025 | Monoferric |
| Adaptive Biotechnologies Corporation | $32.36 | 2023 | Clonoseq |
| Kyowa Kirin, INC. | $29.91 | 2022 | |
| Servier Pharmaceuticals LLC | $22.82 | 2025 | |
| Clovis Oncology, INC. | $18.33 | 2022 | |
| Foundation Medicine, INC. | $18.18 | 2023 | Foundationone Cdx |
| Pharmacyclics LLC, An Abbvie Company | $14.39 | 2023 | Imbruvica |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.26 | 2024 | Gilotrif |
| Adc Therapeutics America, INC. | $13.52 | 2022 | |
| Pharmaessentia USA Corporation | $13.19 | 2024 | Besremi |
| Verity Pharmaceuticals INC. | $12.83 | 2023 | Trelstar |
| Secura Bio, INC. | $9.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle West listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.